網膜硝子体疾患の世界市場レポート 2025年

網膜硝子体疾患市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.9％で、63億米ドルに成長します。予測期間の成長は、加齢黄斑変性症の有病率の上昇、糖尿病網膜症の罹患率の増加、再生幹細胞治療への投資の増加、眼疾患に対するヘルスケア支出の増加、網膜疾患の早期発見に対する意識の高まり、政府の支援策などに起因すると考えられます。この期間に予想される主な動向には、AIを活用した網膜疾患検出、ロボット支援網膜硝子体手術、ナノテクノロジーに基づくドラッグデリバリーシステム、リアルタイム眼球モニタリング用スマートコンタクトレンズ、超高解像度補償光学イメージング、生分解性硝子体内インプラントなどがあります。

糖尿病性網膜症の有病率の増加は、今後数年間の網膜硝子体疾患市場の成長を促進すると予想されます。糖尿病網膜症は、糖尿病患者における高血糖の長期化に伴う網膜血管の損傷に起因する眼疾患です。この疾患は、糖尿病患者数の増加により一般的になりつつあり、その主な原因は、座りがちなライフスタイルと不十分な血糖コントロールであり、網膜血管の損傷につながります。網膜硝子体疾患治療は、硝子体出血や牽引性網膜剥離などの問題に対処することで、視力を維持し、網膜のさらなる障害を最小限に抑える糖尿病網膜症の管理に不可欠です。例えば、2024年10月、オーストラリアの政府機関であるオーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、2022～23年の間に、スクリーニングを受けた先住民の1.8％が糖尿病網膜症の治療を受け、年齢標準化治療率は1.3％であったのに対し、非先住民のオーストラリア人は1.5％であったと報告しました。したがって、糖尿病性網膜症の発生率の増加が網膜硝子体疾患市場の拡大に寄与しています。

網膜硝子体疾患市場の主要企業は、メトトレキサートベースの治療など、まれで攻撃的な網膜がんの一種である原発性網膜硝子体リンパ腫をターゲットとした先進的治療を開発しています。この治療法は、化学療法薬であるメトトレキサートの硝子体内投与により網膜と硝子体のがん細胞を抑制し、集中的かつ効果的な治療を提供するものです。例えば、2022年12月、米国のバイオテクノロジー企業であるアルデイラ・セラピューティクス社は、ADX-2191に関するFDAとの新薬承認前申請（pre-NDA）会議に成功したと発表しました。この製品は、原発性網膜硝子体リンパ腫（PVRL）を治療するために設計された新規の防腐剤を含まないメトトレキサート製剤であり、この稀な疾患に対する有望な解決策を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界網膜硝子体疾患PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の網膜硝子体疾患市場：成長率分析
• 世界の網膜硝子体疾患市場の実績：規模と成長, 2019-2024
• 世界の網膜硝子体疾患市場の予測：規模と成長, 2024-2029, 2034F
• 世界網膜硝子体疾患総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の網膜硝子体疾患市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 網膜裂孔
• 網膜剥離
• 糖尿病網膜症
• 黄斑変性症
• 黄斑円孔
• その他のタイプ
• 世界の網膜硝子体疾患市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デジタル蛍光眼底造影検査
• 光干渉断層撮影
• ハイデルベルク網膜断層撮影
• インドシアニングリーン蛍光眼底造影検査
• その他の診断
• 世界の網膜硝子体疾患市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 薬
• その他の治療法
• 世界の網膜硝子体疾患市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の網膜硝子体疾患市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の網膜硝子体疾患市場網膜裂孔の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 萎縮性網膜裂孔
• 網膜裂孔
• 馬蹄形網膜裂孔
• 巨大網膜裂孔
• 世界の網膜硝子体疾患市場網膜剥離の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 裂孔原性網膜剥離
• 牽引性網膜剥離
• 滲出性網膜剥離
• 世界の網膜硝子体疾患市場糖尿病網膜症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非増殖性糖尿病網膜症
• 増殖性糖尿病網膜症
• 糖尿病性黄斑浮腫
• 世界の網膜硝子体疾患市場黄斑変性症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乾性黄斑変性症
• 湿性黄斑変性症
• 世界の網膜硝子体疾患市場黄斑円孔のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全層黄斑円孔
• 層状黄斑円孔
• 牽引性黄斑円孔
• 世界の網膜硝子体疾患市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 網膜上膜
• 網膜静脈閉塞症
• 網膜動脈閉塞症
• 網膜色素変性症
• ぶどう膜炎
• 硝子体出血
• 黄斑浮腫
• 中心性漿液性網膜症
• 増殖性硝子体網膜症

第7章 地域別・国別分析

• 世界の網膜硝子体疾患市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の網膜硝子体疾患市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜硝子体疾患市場：競合情勢
• 網膜硝子体疾患市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Baxter International
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co. Ltd.
• Topcon Corporation
• Ocular Therapeutix Inc.
• Carl Zeiss Meditec AG
• EyePoint Pharmaceuticals Inc.
• Kodiak Sciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 網膜硝子体疾患市場2029：新たな機会を提供する国
• 網膜硝子体疾患市場2029：新たな機会を提供するセグメント
• 網膜硝子体疾患市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vitreoretinal disorder encompasses a group of eye conditions that impact the retina and the vitreous humor, both of which are essential for preserving the eye's shape and ensuring visual clarity. These conditions can lead to progressive vision impairment and often require advanced diagnostic tools and specialized medical or surgical treatments for proper management.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or hole in the retina, the light-sensitive layer at the back of the eye. Diagnosis involves various techniques such as digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, among others. Treatment options include surgery, medication, and additional approaches. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and serve a range of end users including hospitals, home care settings, specialty clinics, and others.

The vitreoretinal disorder market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vitreoretinal disorder market size has grown strongly in recent years. It will grow from$4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of diabetic retinopathy, an aging population, increased awareness of retinal diseases, the expansion of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.

The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to$6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The projected growth in the forecast period can be attributed to the rising prevalence of age-related macular degeneration, an increasing incidence of diabetic retinopathy, growing investment in regenerative stem cell therapies, higher healthcare spending on eye diseases, greater awareness of early retinal disease detection, and supportive government initiatives. Key trends expected during this period include AI-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery systems, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.

The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market in the years ahead. Diabetic retinopathy is an eye disease resulting from damage to the retinal blood vessels caused by prolonged high blood sugar levels in individuals with diabetes. This condition is becoming more common due to the growing number of diabetes cases, largely fueled by sedentary lifestyles and inadequate blood sugar control, which lead to retinal vascular damage. Vitreoretinal disorder treatment is essential for managing diabetic retinopathy by addressing issues such as vitreous hemorrhage and tractional retinal detachment, thus helping to preserve vision and minimize further retinal harm. For example, in October 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that during 2022-23, 1.8% of screened First Nations individuals received treatment for diabetic retinopathy, with an age-standardized treatment rate of 1.3%, compared to 1.5% for non-Indigenous Australians. Therefore, the increasing incidence of diabetic retinopathy is contributing to the expansion of the vitreoretinal disorder market.

Leading companies in the vitreoretinal disorder market are developing advanced therapies, such as methotrexate-based treatments, to target primary vitreoretinal lymphoma-a rare and aggressive form of retinal cancer. This approach involves the intravitreal administration of methotrexate, a chemotherapy drug, to suppress cancerous cells in the retina and vitreous, providing a focused and effective treatment. For instance, in December 2022, Aldeyra Therapeutics Inc., a biotechnology company based in the U.S., announced a successful pre-New Drug Application (pre-NDA) meeting with the FDA regarding ADX-2191. This product is a novel, preservative-free methotrexate formulation designed to treat primary vitreoretinal lymphoma (PVRL), offering a promising solution for this rare condition.

In July 2024, Merck & Co. Inc., a U.S.-based pharmaceutical giant, acquired Eyebiotech Limited (EyeBio) for $3 billion. This strategic move aims to expand Merck's portfolio in the field of ophthalmology by adding Restoret (EYE103), a promising therapy for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Eyebiotech Limited, headquartered in the UK, is a clinical-stage biotech firm focused on developing treatments for retinal disorders, including vitreoretinal diseases.

Major players in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., and Clearside Biomedical.

North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in vitreoretinal disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vitreoretinal Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vitreoretinal disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vitreoretinal disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vitreoretinal disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Retinal Tear; Retinal Detachment; Diabetic Retinopathy; Macular Degeneration; Macular Hole; Other Types
• 2) By Diagnosis: Digital Fluorescein Angiography; Optical Coherence Tomography; Heidelberg Retinal Tomography; Indocyanine Green Angiography; Other Diagnosis
• 3) By Treatment: Surgery; Medication; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Retinal Tear: Atrophic Retinal Tear; Operculated Retinal Tear; Horseshoe Retinal Tear; Giant Retinal Tear
• 2) By Retinal Detachment: Rhegmatogenous Retinal Detachment; Tractional Retinal Detachment; Exudative Retinal Detachment
• 3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy; Diabetic Macular Edema
• 4) By Macular Degeneration: Dry Macular Degeneration; Wet Macular Degeneration
• 5) By Macular Hole: Full-Thickness Macular Hole; Lamellar Macular Hole; Tractional Macular Hole
• 6) By Other Types: Epiretinal Membrane; Retinal Vein Occlusion; Retinal Artery Occlusion; Retinitis Pigmentosa; Uveitis; Vitreous Hemorrhage; Macular Edema; Central Serous Retinopathy; Proliferative Vitreoretinopathy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vitreoretinal Disorder Market Characteristics

3. Vitreoretinal Disorder Market Trends And Strategies

4. Vitreoretinal Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vitreoretinal Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vitreoretinal Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vitreoretinal Disorder Market Growth Rate Analysis
• 5.4. Global Vitreoretinal Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vitreoretinal Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vitreoretinal Disorder Total Addressable Market (TAM)

6. Vitreoretinal Disorder Market Segmentation

• 6.1. Global Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retinal Tear
• Retinal Detachment
• Diabetic Retinopathy
• Macular Degeneration
• Macular Hole
• Other Types
• 6.2. Global Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Digital Fluorescein Angiography
• Optical Coherence Tomography
• Heidelberg Retinal Tomography
• Indocyanine Green Angiography
• Other Diagnosis
• 6.3. Global Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Medication
• Other Treatments
• 6.4. Global Vitreoretinal Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Vitreoretinal Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Tear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atrophic Retinal Tear
• Operculated Retinal Tear
• Horseshoe Retinal Tear
• Giant Retinal Tear
• 6.7. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Detachment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rhegmatogenous Retinal Detachment
• Tractional Retinal Detachment
• Exudative Retinal Detachment
• 6.8. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Diabetic Retinopathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema
• 6.9. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Macular Degeneration
• Wet Macular Degeneration
• 6.10. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Hole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Full-Thickness Macular Hole
• Lamellar Macular Hole
• Tractional Macular Hole
• 6.11. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epiretinal Membrane
• Retinal Vein Occlusion
• Retinal Artery Occlusion
• Retinitis Pigmentosa
• Uveitis
• Vitreous Hemorrhage
• Macular Edema
• Central Serous Retinopathy
• Proliferative Vitreoretinopathy

7. Vitreoretinal Disorder Market Regional And Country Analysis

• 7.1. Global Vitreoretinal Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vitreoretinal Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vitreoretinal Disorder Market

• 8.1. Asia-Pacific Vitreoretinal Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vitreoretinal Disorder Market

• 9.1. China Vitreoretinal Disorder Market Overview
• 9.2. China Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vitreoretinal Disorder Market

• 10.1. India Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vitreoretinal Disorder Market

• 11.1. Japan Vitreoretinal Disorder Market Overview
• 11.2. Japan Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vitreoretinal Disorder Market

• 12.1. Australia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vitreoretinal Disorder Market

• 13.1. Indonesia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vitreoretinal Disorder Market

• 14.1. South Korea Vitreoretinal Disorder Market Overview
• 14.2. South Korea Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vitreoretinal Disorder Market

• 15.1. Western Europe Vitreoretinal Disorder Market Overview
• 15.2. Western Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vitreoretinal Disorder Market

• 16.1. UK Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vitreoretinal Disorder Market

• 17.1. Germany Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vitreoretinal Disorder Market

• 18.1. France Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vitreoretinal Disorder Market

• 19.1. Italy Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vitreoretinal Disorder Market

• 20.1. Spain Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vitreoretinal Disorder Market

• 21.1. Eastern Europe Vitreoretinal Disorder Market Overview
• 21.2. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vitreoretinal Disorder Market

• 22.1. Russia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vitreoretinal Disorder Market

• 23.1. North America Vitreoretinal Disorder Market Overview
• 23.2. North America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vitreoretinal Disorder Market

• 24.1. USA Vitreoretinal Disorder Market Overview
• 24.2. USA Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vitreoretinal Disorder Market

• 25.1. Canada Vitreoretinal Disorder Market Overview
• 25.2. Canada Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vitreoretinal Disorder Market

• 26.1. South America Vitreoretinal Disorder Market Overview
• 26.2. South America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vitreoretinal Disorder Market

• 27.1. Brazil Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vitreoretinal Disorder Market

• 28.1. Middle East Vitreoretinal Disorder Market Overview
• 28.2. Middle East Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vitreoretinal Disorder Market

• 29.1. Africa Vitreoretinal Disorder Market Overview
• 29.2. Africa Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vitreoretinal Disorder Market Competitive Landscape And Company Profiles

• 30.1. Vitreoretinal Disorder Market Competitive Landscape
• 30.2. Vitreoretinal Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Vitreoretinal Disorder Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Baxter International
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Alcon Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Topcon Corporation
• 31.12. Ocular Therapeutix Inc.
• 31.13. Carl Zeiss Meditec AG
• 31.14. EyePoint Pharmaceuticals Inc.
• 31.15. Kodiak Sciences Inc.

32. Global Vitreoretinal Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vitreoretinal Disorder Market

34. Recent Developments In The Vitreoretinal Disorder Market

35. Vitreoretinal Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Vitreoretinal Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vitreoretinal Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vitreoretinal Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35026_Vitreoretinal_Disorder_GMR_2025